+

US20020183395A1 - Methods for treating hyperactive gastric motility - Google Patents

Methods for treating hyperactive gastric motility Download PDF

Info

Publication number
US20020183395A1
US20020183395A1 US10/114,148 US11414802A US2002183395A1 US 20020183395 A1 US20020183395 A1 US 20020183395A1 US 11414802 A US11414802 A US 11414802A US 2002183395 A1 US2002183395 A1 US 2002183395A1
Authority
US
United States
Prior art keywords
indol
dihydro
chloro
mammal
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/114,148
Inventor
Thomas Argentieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US10/114,148 priority Critical patent/US20020183395A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARGENTIERI, THOMAS M.
Publication of US20020183395A1 publication Critical patent/US20020183395A1/en
Priority to US10/635,081 priority patent/US7015242B2/en
Priority to US11/384,895 priority patent/US20060160892A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • This invention relates to novel methods for modulating gastric tissues utilizing compounds which modulate the KCNQ family of potassium channels, particularly compounds which open or agonize the channels.
  • the methods of this invention include the treatment, prevention, inhibition and amelioration of hyperactive gastric motility, including that associated with colitis, Irritable Bowel Syndrome and Crohn's Disease.
  • R is hydrogen, hydroxy or fluoro
  • R 1 , R 2 , R 3 and R 4 each are independently hydrogen, C 1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R 1 and R 2 , R 2 and R 3 or R 3 and R 4 are joined together to form a benzo fused ring
  • R 5 is hydrogen or C 1-4 alkyl
  • R 6 is chlorine or trifluoromethyl
  • U.S. Pat. No. 6,117,900 teaches the use of retigabine, also known as N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, for the treatment of neuropathic pain.
  • This invention comprises methods for treating, preventing, inhibiting, alleviating or controlling hyperactive gastric motility in a mammal, the methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound which acts as an agonist or opener of the KCNQ family of potassium channels, including the KCNQ2, KCNQ3, KCNQ4, and KCNQ5 potassium channels, alone or in combination.
  • a particular embodiment of this invention includes use in the methods described herein of one or more agonists or openers of KCNQ2 ⁇ 3 potassium channels.
  • Another series of methods of this invention comprises use of one or more agonists or openers of KCNQ3 ⁇ 5 potassium channels.
  • Further methods of this invention comprise treatment of the bladder instability conditions described herein by pharmaceutical administration of one or more agonists or openers of KCNQ4 potassium channels.
  • Specific methods of this invention include the treatment, prevention, inhibition, alleviation or control of hyperactive gastric motility associated with colitis, irritable bowel syndrome (IBS) or Crohn's Disease.
  • IBS irritable bowel syndrome
  • R 1 is selected from hydrogen, C 1 —C 6 -alkyl, C 2 —C 6 -alkanoyl or the radical Ar;
  • R 2 is selected from hydrogen or C 1 —C 6 -alkyl
  • R 3 is selected from C 1 — 6 -alkoxy, NH 2 , C 1 —C 6 -alkylamino, C 1 —C 6 -dialkylamino, amino substituted by the radical Ar, C 1 —C 6 -alkyl, C 2 —C 6 -alkenyl, C 2 —C 6 -alkynyl, the radical Ar or the radical ArO—;
  • R 4 is selected from hydrogen, C 1 —C 6 -alkyl or the radical Ar;
  • R 5 is selected from hydrogen or C 1 —C 6 -alkyl or the radical Ar;
  • Alk indicates a straight or branched alkylene group with 1-9 carbon atoms, which can also be substituted by the radical Ar;
  • Ar is a phenyl radical substituted by the radicals R 6 , R 7 and/or R 8 where these radicals R 6 , R 7 and R 8 are the same or different and represent H, C 1 —C 6 -alkyl, C 3 —C 7 -cycloalkyl, hydroxy, C 1 —C 6 -alkoxy, C 2 —C 6 -alkanoyloxy, halogen, hydroxy, C 1 —C 6 -halogenoalkyl, —CN, —NH 2 , —NH—C 1 —C 6 —alkyl, —N(C 1 —C 6 -alkyl) 2 , —CO 2 H, —CO—C 1 —C 6 -alkyl, —CO—O—C 1 —C 6 -alkyl, —COAr, —CO—OAr, —CONH 2 , —CONH—C 1 —C 6 -alkyl, —CON
  • n is 0 or 1;
  • alkyl groups, halogenalkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylamino groups, alkanoyl amino groups, alkanoyloxy groups and alkanoyl groups in general can be straight or branched.
  • the C 3 —C 7 -cycloalkyl group is preferably cyclopentyl or cyclohexyl.
  • C 2 —C 6 -alkenyl preferably represents allyl.
  • C 2 —C 6 -alkynyl preferably represents propargyl.
  • the halogen atoms are chlorine, bromine or fluorine, in particular chlorine of fluorine.
  • the alkyl and alkoxy groups as such or as components of groups of more complicated radicals consist in particular of 1-4 carbon atoms, preferably 1 or 2 carbon atoms.
  • Alkanoyl groups, such as alkanoylamino groups or alkanoyloxy groups consist in particular of 2-4, preferably 2-3 carbon atoms.
  • Alk consists in particular of 1-3, preferably 1 or 2 carbon atoms.
  • N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid and its pharmaceutically acceptable salts and ester forms are preferred.
  • retigabine also known as N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester (CAS Registry No. 150812-12-7), having the formula:
  • Also useful in the methods of this invention are the metabolite forms of retigabine which may be isolated from blood, urine or feces of recipients of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester.
  • the metabolites include the glucoside of retigabine, [4-(4-Fluoro-benzylamino)-2-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-ylamino)-phenyl]-carbamic acid ethyl ester, as well as its two glucoronide analogs, 6-[2-Ethoxycarbonylamino-5-(4-fluoro-benzylamino)-phenylamino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid and 6-[(3-Amino-4-ethoxycarbonylamino-phenyl)-(4-fluoro-benzyl)-amino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid.
  • substituted 3-phenyl oxindole compounds disclosed in U.S. Pat. No. 5,565,483 (Hewawasam et al.), which issued on Oct. 15, 1996, the contents of which are incorporated herein by reference. These compounds include the substituted 3-phenyl oxindole compounds having the formulae:
  • R is hydrogen, hydroxy or fluoro
  • R 1 , R 2 , R 3 and R 4 each are independently hydrogen, C 1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R 1 and R 2 , R 2 and R 3 or R 3 and R 4 are joined together to form a benzo fused ring;
  • R 5 is hydrogen or C 1-4 alkyl
  • R 6 is chlorine or trifluoromethyl
  • R 1 , R 2 , R 3 and R 4 are each independently selected from H, C 1 to C 4 alkyl, halogen or trifluoromethyl, and when R 1 and R 4 are H; R 2 or R 3 is phenyl, p-methoxyphenyl or trifluormethylphenyl; or R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are joined together to form a benzo fused ring; R5 is H or C 1 to C 4 alkyl; and R 6 is chlorine or trifluoromethyl, or a pharmaceutically acceptable salt form thereof.
  • Non-limiting examples of these substituted 3-phenyl oxindole compounds are:
  • Pharmaceutically acceptable salt forms of these substituted 3-phenyl oxindole compounds include those formed as base addition, including those formed using suitable inorganic bases, such as alkali and alkaline earth metal bases, such as sodium, potassium, magnesium and calcium metallic cations.
  • suitable inorganic bases such as alkali and alkaline earth metal bases, such as sodium, potassium, magnesium and calcium metallic cations.
  • the compounds may be administered as described in U.S. Pat. No. 5,565,483.
  • a pharmaceutically effective amount in mammals, including man may be from about 0.1 pg/kg to about 100 mg/kg of body weight. Parenteral administration may be completed at an effective dose of from about 1 pg/kg to about 10 mg/kg of body weight.
  • the methods of this invention are useful for treating, preventing, inhibiting or ameliorating hyperactive gastric motility in a mammal, the methods each comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a KCNQ potassium channel opener, as described above.
  • the conditions which may be treated with the methods of this invention include irritable bowel syndrome, also known as spastic colon, Crohn's Disease and mucous colitis.
  • the methods of this invention may also be used for mammalian gastrointestinal (GI) conditions including diarrhea, chronic diarrhea, acute diarhea, abdominal pain associated with diarrhea, postprandial urgency, postprandial accentuation of diarrhea or abdominal pain, or a combination of two or more of these symptoms.
  • GI mammalian gastrointestinal
  • IBS Irritable Bowel Syndrome
  • Functional Gastrointestinal Disorders include diseases such as noncardiac chest pain, nonulcer dyspepsia, and chronic constipation or diarrhea. It has also been referred to as spastic colon, nervous colitis, mucous colitis, functional colitis or colonic neurosis.
  • the diagnosis is one of exclusion based on symptoms. Manning et al. first reported six symptoms which differentiated IBS from other gastrointestinal diseases.
  • Manning Criteria are: a) relief of abdominal pain with defecation, b) looser stools with the onset of pain, c) more frequent bowel movements at onset of pain, d) abdominal bloating or distention, e) feelings of incomplete evacuation, and f) passage of mucus per rectum. Generally speaking, the more ‘Manning Criteria’ present the more likely an indication of IBS.
  • the compounds and methods of this invention may be used in conjunction with laxatives and anti-diarrheal medications frequently used for the treatment or amelioration of symptoms of IBS.
  • antispasmodic drugs such as dicyclomine
  • KCNQ channel opening compounds of this invention may be administered in conjunction with conventional drug therapies for IBS, including opioid agonists such as loperamide or anticholinergic agents, such as pepenzolate bromide or timepidium bromide to control gastrointestinal hypermotility.
  • opioid agonists such as loperamide or anticholinergic agents
  • pepenzolate bromide or timepidium bromide such as pepenzolate bromide or timepidium bromide to control gastrointestinal hypermotility.
  • anti-anxiety agents may be co-employed.
  • venlafaxine HCl diazepam
  • fluoxetine HCl hydroxyzine HCl, hydroxyzine pamoate, mephobarbital, meprobamate, paroxetine HCI, doxepin HCI, lorazepam, chlordiazepoxide HCl, alone or in combination with amitryptyline HCl, clorazepate dipotassium, or alprazolam.
  • doxepin HCI paroxetine HCI
  • lorazepam chlordiazepoxide HCl, alone or in combination with amitryptyline HCl, clorazepate dipotassium, or alprazolam.
  • Each of these medicaments may be administered in the conventional methods and administrations known in the art, including those described in the Physicians' Desk Reference 2001, 55 Edition, published by Medical Economics Company, Inc. at Montvale, N.J. 07645-1742.
  • non-medication and lifestyle changes may also be recommended for IBS sufferers, including an increase in fiber intake (dietary or fiber supplements) to help relieve constipation and cramps.
  • Crohn's disease involves chronic inflammation of the intestines with symptoms including abdominal pain, diarrhea, and weight loss. Less common symptoms include poor appetite, fever, night sweats, rectal pain, and rectal bleeding. Crohn's disease may affect the colon, the rectum, and the small intestine and, in rare instances, also the stomach, mouth, and esophagus. Crohn's colitis is inflammation that appears only in the colon, often involving abdominal pain and bloody diarrhea. Anal fistulae and perirectal abscesses can also occur. Crohn's enteritis is inflammation confined to the small intestine. Crohn's terminal ileitis is inflammation that affects the end of the small intestine (terminal ileum).
  • Crohn's enterocolitis and ileocolitis involves inflammation of both the small intestine and the colon. Crohn's terminal ileitis and ileocolitis are the most common types of Crohn's disease. Abdominal pain and diarrhea often result in each type of Crohn's disease.
  • the compounds and methods of this invention may be used to treat, inhibit, prevent or ameliorate each of these Crohn's conditions.
  • the compounds of this invention may also be used in combination therapies or regimens with medications conventionally used to treat Crohn's disease and its symptoms including anti- inflammatory agents, such as 5-ASA compounds, systemic corticosteorids, topical corticosteroids, and antibiotics, as well as immunomodulators.
  • anti-inflammatory agents which are effective in treating Crohn's disease include corticosteroids and the 5- aminosalycylates (5-ASA) compounds.
  • corticosteroids include Prednisone, Prednisolone, and Budesonide.
  • 5-ASA compounds include ASACOL® brand mesalamine, PENTASA® brand mesalamine controlled release capsules, and ROWASA® brand mesalamine rectal suspensions enema.
  • Antibiotics may be used in conjunction to the potassium channel openers of this invention for treating Crohn's colitis, such as metronidazole (available as FLAGLYL® brand metronidazole tablets or FLAGLYL® ER brand extended release metronidazole tablets) and ciprofloxacin.
  • useful immunomodulators include 6-mercaptopurine (6-MP), azathioprine, methotrexate, and anti-TNF-alpha (REMICADE® infliximab recombinant for IV injection).
  • KCNQ potassium channel openers of this invention may be used in conjunction with medications such as mesalamine or 6-mercaptopurine (6-MP) to reduce the chances of Crohn's disease relapse after surgery or limit the severity of such relapses.
  • medications such as mesalamine or 6-mercaptopurine (6-MP) to reduce the chances of Crohn's disease relapse after surgery or limit the severity of such relapses.
  • a medical professional may also use the KCNQ channel openers of this invention in combination with an inhibitor of gastric secretion, such as a proton pump inhibitor, a histamin H 2 -receptor blocker, omeprazole, lansoprazole, cimetidine, ranitidine, nizatidine, or famotidine.
  • an inhibitor of gastric secretion such as a proton pump inhibitor, a histamin H 2 -receptor blocker, omeprazole, lansoprazole, cimetidine, ranitidine, nizatidine, or famotidine.
  • KCNQ channel opening compounds described herein may also be used to inhibit, limit or delay defecation in a mammal in need of such treatment. This may be used to inhibit or control anal incontinence in a mammal, including humans, who experience a lessened ability to control bowel movements or experience or are susceptible to anal incontinence. These methods include effecting a desirable delay or inhibition of postprandial urgency or postprandial intestinal cramping or related pain.
  • the methods of this invention are useful for inducing or assisting in control or prevention or treatment of the maladies described herein in humans in need of such relief, including adult and pediatric uses. However, they may also be utilized for veterinary applications, particularly including canine and feline fecal control methods. If desired, the methods herein may also be used with farm animals, such as ovine, bovine, porcine and equine breeds.
  • the applications may utilize conventional oral, rectal, parenteral or intravenous delivery methods as conventionally utilized in veterinary practice.
  • Most preferable in most instance for home use with companion animals are oral tablets or capsules or neat compound or powdered or granular pharmaceutical formulations which may be mixed with chewable or liquid veterinary formulations or food materials or liquids acceptable to the animal in question.
  • the terms “pharmaceutically effective amount” or “therapeutically effective amount” mean the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, prevention or amelioration of hyperactive gastric motility or the excessive or undesirable urge to defecate, or a decrease in the frequency of incidence of fecal incontinence.
  • a pharmaceutically or therapeutically effective dose may be considered the minimal amount of the compound in question which will alleviate, inhibit or remove the cramping, pressure, pain or feeling of fecal urgency associated with hyperactive gastric motility.
  • the term refers to that ingredient alone.
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • the methods of this invention may be accomplished with a daily dose of the active compounds described above from U.S. Pat. No. 5,384,330 of from about 0.1 mg/kg to about 10 mg/kg.
  • Doses may be administered as a single regimen, such as only prior to bedtime or before travel, or as a continuous regimen divided by two or more doses over the course of a day.
  • Human administration may be at dosages of from about 10 mg BID to about 1000 mg BID, preferably from about 50 mg BID to about 500 mg BID, more preferably at a dose of from about 100 mg BID to about 300 mg BID.
  • Compounds as described in U.S. Pat. No. 5,384,330, including retigabine, can be administered orally using conventional pharmaceutical excipients or carriers, preferably coated or contained in hard or soft gelatin capsules.
  • oral formulations contained in hard gelatin capsules can include those in which the active compound comprises from about 45% to 50%, by weight, of the formulation.
  • Microcrystalline cellulose comprises from about 43% to about 47%
  • povidone comprises from about 3% to about 4%
  • silicon dioxide and magnesium stearate each comprise from about 0.3% to about 0.7%, each by weight.
  • Specific examples of capsules containing 50 mg, 100 mg and 200 mg may be formulated utilizing the following lists of components.
  • [0103] 1 Weigh separately the active ingredient (retigabine), preferably screened through an 800 micron screen, and the microcrystalline cellulose components.
  • Step 3 Place the ingredients from Step 1 into a suitable blender and mix thoroughly.
  • Step 3 Screen the mixture from Step 3 through a 1000 ⁇ m screen and place the screened mixture into the vessel of a fluidized bed granulator.
  • Step 9 Screen the mixed components from Step 9 , preferably through a 800 ⁇ m screen.
  • the final component mixture from Step 11 can then be coated, encapsulated or compressed into tablets utilizing conventional tablet excipients or carriers, as desired. It will be understood that oral dosage forms within the scope of this invention can be prepared using the components listed above in respective amounts according the dose of active ingredient in the particular formulation.
  • the final mixture of Step 11 can be administered neat or mixed into foods acceptable to the animal in question. Further, the mixtures can be formulated into tablets, capsules or coated products, as described above, or integrated into conventional veterinary medicaments or food products.
  • the compounds from U.S. Pat. No. 5,384,330 described herein may be prepared and maintained in conventional lyophylized formulations and reconstituted prior to administration with an intravenously acceptable saline solution, such as a 0.9% saline solution.
  • an intravenously acceptable saline solution such as a 0.9% saline solution.
  • the pH of the intravenous formulation can be adjusted, as needed, with an intravenous and pharmaceutically acceptable acid, such as methanesulfonic acid.
  • KCNQ1, KCNQ3 and KCNQ5 potassium channels were identified in the rat urinary bladder. The highest levels of expression were seen in KCNQ5 (0.2 ⁇ 0.1 ng KCNQ5 mRNA/GAPDH mRNA).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides methods and pharmaceutical compositions for treating, inhibiting or preventing hyperactive gastric motility in a mammal utilizing agonists of KCNQ potassium channels, including KCNQ2, KCNQ3, KCNQ4 and KCNQ5 potassium channels, alone or in combination. The hyperactive gastric motility may be associated with maladies including, colitis, irritable bowel syndrome and Crohn's disease. Compounds useful in these methods include the 1,2,4-triamino-benzene derivatives described in U.S. Pat. No. 5,384,330 (Dieter et al.) and the substituted 3-phenyl oxindole compounds described in U.S. Pat. No. 5,565,483 (Hewawasam et al.). Among the preferred compounds of this invention is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also referred to as retigabine.

Description

  • This application claims priority from copending provisional application Ser. No. 60/281,471, filed Apr. 4, 2001, the entire disclosure of which is hereby incorporated by reference[0001]
  • This invention relates to novel methods for modulating gastric tissues utilizing compounds which modulate the KCNQ family of potassium channels, particularly compounds which open or agonize the channels. The methods of this invention include the treatment, prevention, inhibition and amelioration of hyperactive gastric motility, including that associated with colitis, Irritable Bowel Syndrome and Crohn's Disease. [0002]
    • BACKGROUND OF THE INVENTION
  • U.S. Pat. No. 5,384,330 (Dieter et al.) teaches pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula: [0003]
    Figure US20020183395A1-20021205-C00001
  • and their properties as anti-epileptic, muscle relaxing, fever-reducing and peripheral analgesic agents. [0004]
  • U.S. Pat. No. 5,565,483 (Hewawasam et al.) teaches compounds of the formulae: [0005]
    Figure US20020183395A1-20021205-C00002
  • wherein: R is hydrogen, hydroxy or fluoro; R[0006] 1, R2, R3 and R4 each are independently hydrogen, C1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R1 and R2, R2 and R3 or R3 and R4 are joined together to form a benzo fused ring; R5 is hydrogen or C1-4 alkyl; and R6 is chlorine or trifluoromethyl; or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof, which are potassium channel openers useful for treating ischemia, convulsions and asthma.
  • The article [0007] Modulation of KCNQ⅔ Potassium Channels by the Novel Anticonvulsant Retigabine, Main et al., Molecular Pharmacology, 58: pp. 253-262, 2000, describes the actions of retigabine (D23129; N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester) in modulating the KCNQ⅔ potassium channels in oocytes in a 3-fold manner, i.e. retigabine shifts the voltage dependence of channel activation to more hyperpolarized membrane potentials, increases the rate of channel activation and slows channel deactivation.
  • U.S. Pat. No. 5,849,789 and 5,852,053 (both to Rostock et al.) teaches the use of retigabine for the treatment of neurodegenerative disorders, including those associated with stroke. [0008]
  • U.S. Pat. No. 5,914,425 (Meisel et al.) teaches novel crystalline forms of retigabine. [0009]
  • U.S. Pat. No. 6,117,900 teaches the use of retigabine, also known as N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, for the treatment of neuropathic pain.[0010]
    • DESCRIPTION OF THE INVENTION
  • This invention comprises methods for treating, preventing, inhibiting, alleviating or controlling hyperactive gastric motility in a mammal, the methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound which acts as an agonist or opener of the KCNQ family of potassium channels, including the KCNQ2, KCNQ3, KCNQ4, and KCNQ5 potassium channels, alone or in combination. A particular embodiment of this invention includes use in the methods described herein of one or more agonists or openers of KCNQ⅔ potassium channels. Another series of methods of this invention comprises use of one or more agonists or openers of KCNQ⅗ potassium channels. Further methods of this invention comprise treatment of the bladder instability conditions described herein by pharmaceutical administration of one or more agonists or openers of KCNQ4 potassium channels. [0011]
  • Specific methods of this invention include the treatment, prevention, inhibition, alleviation or control of hyperactive gastric motility associated with colitis, irritable bowel syndrome (IBS) or Crohn's Disease. [0012]
  • Among the compounds useful in the methods of this invention are those disclosed in U.S. Pat. No. 5,384,330 (Dieter et al.), the contents of which are incorporated herein by reference. The compounds include those of the formula: [0013]
    Figure US20020183395A1-20021205-C00003
  • wherein: [0014]
  • R[0015] 1 is selected from hydrogen, C1—C6-alkyl, C2—C6-alkanoyl or the radical Ar;
  • R[0016] 2 is selected from hydrogen or C1—C6-alkyl;
  • R[0017] 3 is selected from C1—6-alkoxy, NH2, C1—C6-alkylamino, C1—C6-dialkylamino, amino substituted by the radical Ar, C1—C6-alkyl, C2—C6-alkenyl, C2—C6-alkynyl, the radical Ar or the radical ArO—;
  • R[0018] 4 is selected from hydrogen, C1—C6-alkyl or the radical Ar;
  • R[0019] 5 is selected from hydrogen or C1—C6-alkyl or the radical Ar;
  • Alk indicates a straight or branched alkylene group with 1-9 carbon atoms, which can also be substituted by the radical Ar; [0020]
  • Ar is a phenyl radical substituted by the radicals R[0021] 6, R7 and/or R8 where these radicals R6, R7 and R8 are the same or different and represent H, C1—C6-alkyl, C3—C7-cycloalkyl, hydroxy, C1—C6-alkoxy, C2—C6-alkanoyloxy, halogen, hydroxy, C1—C6-halogenoalkyl, —CN, —NH2, —NH—C1—C6—alkyl, —N(C1—C6-alkyl)2, —CO2H, —CO—C1—C6-alkyl, —CO—O—C1—C6-alkyl, —COAr, —CO—OAr, —CONH2, —CONH—C1—C6-alkyl, —CON(C1—C6-alkyl)2, —CONHAr, —NH—CO—C1—C6-alkyl, —NHCO—Ar, —NHCO—C1—C6-alkoxy, —N—H—CO—Ar, —NHCO—NH2, —NHCO—N (—C1—C6-alkyl)2, —NHCO—NHAr, —NH—SO2—C—1—C6-alkyl, —NH—SO2Ar, —NH—SO2-nitrophenyl, —SO2—OH, —SO2—C1—C6-alkyl, —SO2—Ar, —SO2—C1—C6-alkoxy, —SO2—OAr, —SO2—NH2, —SO2—NH—C1—C6-alkyl, —SO2—N(C1—C6-alkyl)2, —SO2—NHAr, —SO2—C1—C6-alkoxy;
  • n is 0 or 1; [0022]
  • or a pharmaceutically acceptable salt thereof. [0023]
  • The alkyl groups, halogenalkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylamino groups, alkanoyl amino groups, alkanoyloxy groups and alkanoyl groups in general can be straight or branched. The same also applies to alkyl and alkyloxy groups (=alkoxy groups) if these are components of more complicated radicals for example in the form of a monoalkyl- or dialkylamino group, alkanoylamino group, carbalkoxy group, alkylcarbonyl group and analogous groups. The C[0024] 3—C7-cycloalkyl group is preferably cyclopentyl or cyclohexyl. C2—C6-alkenyl preferably represents allyl. C2—C6-alkynyl preferably represents propargyl.
  • The halogen atoms are chlorine, bromine or fluorine, in particular chlorine of fluorine. The alkyl and alkoxy groups as such or as components of groups of more complicated radicals consist in particular of 1-4 carbon atoms, preferably 1 or 2 carbon atoms. Alkanoyl groups, such as alkanoylamino groups or alkanoyloxy groups consist in particular of 2-4, preferably 2-3 carbon atoms. Alk consists in particular of 1-3, preferably 1 or 2 carbon atoms. [0025]
  • Among the more preferred compounds of this group are: [0026]
  • 2-Amino-4-(4-fluorobenzylamino)-1 -ethoxycarbonylaminobenzene; [0027]
  • 2-Amino-4-(4-trifluoromethylbenzylamino)-1 -ethoxycarbonylamino-benzene; [0028]
  • 2-Amino-4-benzylamino-1 -ethoxycarbonylamino-benzene; [0029]
  • 2-Amino-4-(3,5-dichlorobenzylamino)-1 -ethoxycarbonylamino benzene; [0030]
  • 2-Amino-4-(3,5-dichlorobenzylamino)-1 -propyloxycarbonylamino benzene; [0031]
  • 2-Amino-(2-chlorobenzylamino)-1-(diethylcarbamoylamino) benzene; [0032]
  • 2-Amino-4-(2,4-dichlorobenzylamino)-1-(dimethylcarbamoylamino) benzene; and [0033]
  • 1 ,2-Diacetylamino-4-(4-fluorobenzylamino) benzene; [0034]
  • Among the most preferred compounds for use in the methods of this invention are N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid and its pharmaceutically acceptable salts and ester forms. Of particular preference is retigabine, also known as N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester (CAS Registry No. 150812-12-7), having the formula: [0035]
    Figure US20020183395A1-20021205-C00004
  • Also useful in the methods of this invention are the metabolite forms of retigabine which may be isolated from blood, urine or feces of recipients of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester. The metabolites include the glucoside of retigabine, [4-(4-Fluoro-benzylamino)-2-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-ylamino)-phenyl]-carbamic acid ethyl ester, as well as its two glucoronide analogs, 6-[2-Ethoxycarbonylamino-5-(4-fluoro-benzylamino)-phenylamino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid and 6-[(3-Amino-4-ethoxycarbonylamino-phenyl)-(4-fluoro-benzyl)-amino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid. Further metabolites include N-[2-Amino-4-(4-fluoro-benzylamino)-phenyl]acetamide, its cyclized analog (4-Fluoro-benzyl)-2-methyl-1H-benzoimidazol-5-yl)amine and the glucoronide analogs of N-[2-Amino-4-(4-fluoro-benzylamino)-phenyl]acetamide, 6-[(4-Acetylamino-3-amino-phenyl)-(4-fluoro-benzyl)-amino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid and 6-[2-Acetylamino-5-(4-fluoro-benzylamino)-phenylamino]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid. [0036]
  • Also useful in the methods of this invention are the substituted 3-phenyl oxindole compounds disclosed in U.S. Pat. No. 5,565,483 (Hewawasam et al.), which issued on Oct. 15, 1996, the contents of which are incorporated herein by reference. These compounds include the substituted 3-phenyl oxindole compounds having the formulae: [0037]
    Figure US20020183395A1-20021205-C00005
  • wherein: [0038]
  • R is hydrogen, hydroxy or fluoro; [0039]
  • R[0040] 1, R2, R3 and R4 each are independently hydrogen, C1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R1 and R2, R2 and R3 or R3 and R4 are joined together to form a benzo fused ring;
  • R[0041] 5 is hydrogen or C1-4 alkyl; and
  • R[0042] 6 is chlorine or trifluoromethyl;
  • or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof.. [0043]
  • One group of the substituted 3-phenyl oxindole compounds useful with this invention include those described above wherein R is hydrogen. Another subgroup of these compounds include those in which R[0044] 1, R2, R3 and R4 are each independently selected from H, C1 to C4 alkyl, halogen or trifluoromethyl, and when R1 and R4 are H; R2 or R3 is phenyl, p-methoxyphenyl or trifluormethylphenyl; or R1 and R2, R2 and R3, or R3 and R4 are joined together to form a benzo fused ring; R5 is H or C1 to C4 alkyl; and R6 is chlorine or trifluoromethyl, or a pharmaceutically acceptable salt form thereof.
  • Non-limiting examples of these substituted 3-phenyl oxindole compounds are: [0045]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; [0046]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; [0047]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; [0048]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; [0049]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2-H-indol-2-one; [0050]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-7-(trifluoromethyl)-2H-indol-2-one; [0051]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-trifluoromethyl)2H-indol-2-one; [0052]
  • (±)-1,3-Dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-2H-indol-2-one; [0053]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis(trifluoromethyl)-2H-indol-2-one; [0054]
  • (−)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; [0055]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one; [0056]
  • (−)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one; [0057]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)2H-indol-2-one; [0058]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[g]indol-2one; [0059]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one; [0060]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[g]indol-2-one; [0061]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one; [0062]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2one; [0063]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(4-methylphenyl)-2H-indol-2-one; [0064]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoromethyl)-2H-indol-2-one; [0065]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e]indol-2-one; [0066]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one; [0067]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-4,6-bis(trifluoromethyl)-2H-indol-2-one; [0068]
  • (±)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-2H-indol-2one; [0069]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-[4-(trifluoromethyl)phenyl]-2H-indol-2-one; [0070]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one; [0071]
  • (±)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one; [0072]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-2H-indol-2-one; [0073]
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indol-2-one; [0074]
  • (±)-3-(5-Chloro-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indol-2-one; [0075]
  • (±)-3-(5-Chloro-2-methoxyphenyl)- 1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one; [0076]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one; and [0077]
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one; [0078]
  • and the pharmaceutically acceptable salt forms thereof. [0079]
  • Among the more preferred compounds of this group are: [0080]
    Figure US20020183395A1-20021205-C00006
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; [0081]
    Figure US20020183395A1-20021205-C00007
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one; [0082]
    Figure US20020183395A1-20021205-C00008
  • (±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one; [0083]
    Figure US20020183395A1-20021205-C00009
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[g]indol-2-one; [0084]
    Figure US20020183395A1-20021205-C00010
  • (+)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one; and [0085]
    Figure US20020183395A1-20021205-C00011
  • (±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e]indol-2-one. [0086]
  • Pharmaceutically acceptable salt forms of these substituted 3-phenyl oxindole compounds include those formed as base addition, including those formed using suitable inorganic bases, such as alkali and alkaline earth metal bases, such as sodium, potassium, magnesium and calcium metallic cations. The compounds may be administered as described in U.S. Pat. No. 5,565,483. A pharmaceutically effective amount in mammals, including man, may be from about 0.1 pg/kg to about 100 mg/kg of body weight. Parenteral administration may be completed at an effective dose of from about 1 pg/kg to about 10 mg/kg of body weight. [0087]
  • The methods of this invention are useful for treating, preventing, inhibiting or ameliorating hyperactive gastric motility in a mammal, the methods each comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a KCNQ potassium channel opener, as described above. The conditions which may be treated with the methods of this invention include irritable bowel syndrome, also known as spastic colon, Crohn's Disease and mucous colitis. The methods of this invention may also be used for mammalian gastrointestinal (GI) conditions including diarrhea, chronic diarrhea, acute diarhea, abdominal pain associated with diarrhea, postprandial urgency, postprandial accentuation of diarrhea or abdominal pain, or a combination of two or more of these symptoms. [0088]
  • Irritable Bowel Syndrome (IBS) is part of a spectrum of diseases known as Functional Gastrointestinal Disorders, which include diseases such as noncardiac chest pain, nonulcer dyspepsia, and chronic constipation or diarrhea. It has also been referred to as spastic colon, nervous colitis, mucous colitis, functional colitis or colonic neurosis. As no diagnostic marker is currently associated with IBS, the diagnosis is one of exclusion based on symptoms. Manning et al. first reported six symptoms which differentiated IBS from other gastrointestinal diseases. These criteria have become art recognized in the diagnosis of IBS, see [0089] Gut 1990;31:77-81; Olibuyide et al., Dig Dis Sci 1995; 40:983-5; Rao et al., J Assoc Physician India 1993;41:357-8; and Jeong et al. Korean J. Intern. Med. 1993;8:34-9. The six ‘Manning Criteria’ are: a) relief of abdominal pain with defecation, b) looser stools with the onset of pain, c) more frequent bowel movements at onset of pain, d) abdominal bloating or distention, e) feelings of incomplete evacuation, and f) passage of mucus per rectum. Generally speaking, the more ‘Manning Criteria’ present the more likely an indication of IBS.
  • The compounds and methods of this invention may be used in conjunction with laxatives and anti-diarrheal medications frequently used for the treatment or amelioration of symptoms of IBS. In patients with abdominal cramps, antispasmodic drugs, such as dicyclomine, may be used with the methods herein. It will also be understood that the KCNQ channel opening compounds of this invention may be administered in conjunction with conventional drug therapies for IBS, including opioid agonists such as loperamide or anticholinergic agents, such as pepenzolate bromide or timepidium bromide to control gastrointestinal hypermotility. In cases where anxiety or related conditions increase the likelihood or severity of symptoms, anti-anxiety agents may be co-employed. These include those known in the art, but not limited to venlafaxine HCl, diazepam, fluoxetine HCl, hydroxyzine HCl, hydroxyzine pamoate, mephobarbital, meprobamate, paroxetine HCI, doxepin HCI, lorazepam, chlordiazepoxide HCl, alone or in combination with amitryptyline HCl, clorazepate dipotassium, or alprazolam. Each of these medicaments may be administered in the conventional methods and administrations known in the art, including those described in the Physicians' Desk Reference 2001, 55 Edition, published by Medical Economics Company, Inc. at Montvale, N.J. 07645-1742. [0090]
  • At the recommendation of a medical professional, non-medication and lifestyle changes may also be recommended for IBS sufferers, including an increase in fiber intake (dietary or fiber supplements) to help relieve constipation and cramps. [0091]
  • Crohn's disease involves chronic inflammation of the intestines with symptoms including abdominal pain, diarrhea, and weight loss. Less common symptoms include poor appetite, fever, night sweats, rectal pain, and rectal bleeding. Crohn's disease may affect the colon, the rectum, and the small intestine and, in rare instances, also the stomach, mouth, and esophagus. Crohn's colitis is inflammation that appears only in the colon, often involving abdominal pain and bloody diarrhea. Anal fistulae and perirectal abscesses can also occur. Crohn's enteritis is inflammation confined to the small intestine. Crohn's terminal ileitis is inflammation that affects the end of the small intestine (terminal ileum). Crohn's enterocolitis and ileocolitis involves inflammation of both the small intestine and the colon. Crohn's terminal ileitis and ileocolitis are the most common types of Crohn's disease. Abdominal pain and diarrhea often result in each type of Crohn's disease. The compounds and methods of this invention may be used to treat, inhibit, prevent or ameliorate each of these Crohn's conditions. [0092]
  • The compounds of this invention may also be used in combination therapies or regimens with medications conventionally used to treat Crohn's disease and its symptoms including anti- inflammatory agents, such as 5-ASA compounds, systemic corticosteorids, topical corticosteroids, and antibiotics, as well as immunomodulators. Anti-inflammatory agents which are effective in treating Crohn's disease include corticosteroids and the 5- aminosalycylates (5-ASA) compounds. Examples of corticosteroids include Prednisone, Prednisolone, and Budesonide. Examples of 5-ASA compounds include ASACOL® brand mesalamine, PENTASA® brand mesalamine controlled release capsules, and ROWASA® brand mesalamine rectal suspensions enema. Antibiotics may be used in conjunction to the potassium channel openers of this invention for treating Crohn's colitis, such as metronidazole (available as FLAGLYL® brand metronidazole tablets or FLAGLYL® ER brand extended release metronidazole tablets) and ciprofloxacin. Examples of useful immunomodulators include 6-mercaptopurine (6-MP), azathioprine, methotrexate, and anti-TNF-alpha (REMICADE® infliximab recombinant for IV injection). [0093]
  • In cases where diseased portions of the intestines are surgically removed Crohn's disease may eventually return to previously healthy tissue. The KCNQ potassium channel openers of this invention may be used in conjunction with medications such as mesalamine or 6-mercaptopurine (6-MP) to reduce the chances of Crohn's disease relapse after surgery or limit the severity of such relapses. [0094]
  • In relevant diarrhea-related conditions, a medical professional may also use the KCNQ channel openers of this invention in combination with an inhibitor of gastric secretion, such as a proton pump inhibitor, a histamin H[0095] 2-receptor blocker, omeprazole, lansoprazole, cimetidine, ranitidine, nizatidine, or famotidine.
  • Pharmaceutically effective amounts of the KCNQ channel opening compounds described herein may also be used to inhibit, limit or delay defecation in a mammal in need of such treatment. This may be used to inhibit or control anal incontinence in a mammal, including humans, who experience a lessened ability to control bowel movements or experience or are susceptible to anal incontinence. These methods include effecting a desirable delay or inhibition of postprandial urgency or postprandial intestinal cramping or related pain. [0096]
  • The methods of this invention are useful for inducing or assisting in control or prevention or treatment of the maladies described herein in humans in need of such relief, including adult and pediatric uses. However, they may also be utilized for veterinary applications, particularly including canine and feline fecal control methods. If desired, the methods herein may also be used with farm animals, such as ovine, bovine, porcine and equine breeds. [0097]
  • The applications may utilize conventional oral, rectal, parenteral or intravenous delivery methods as conventionally utilized in veterinary practice. Most preferable in most instance for home use with companion animals are oral tablets or capsules or neat compound or powdered or granular pharmaceutical formulations which may be mixed with chewable or liquid veterinary formulations or food materials or liquids acceptable to the animal in question. [0098]
  • As used herein, the terms “pharmaceutically effective amount” or “therapeutically effective amount” mean the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, prevention or amelioration of hyperactive gastric motility or the excessive or undesirable urge to defecate, or a decrease in the frequency of incidence of fecal incontinence. When the malady in question warrants, a pharmaceutically or therapeutically effective dose may be considered the minimal amount of the compound in question which will alleviate, inhibit or remove the cramping, pressure, pain or feeling of fecal urgency associated with hyperactive gastric motility. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. [0099]
  • The methods of this invention may be accomplished with a daily dose of the active compounds described above from U.S. Pat. No. 5,384,330 of from about 0.1 mg/kg to about 10 mg/kg. Doses may be administered as a single regimen, such as only prior to bedtime or before travel, or as a continuous regimen divided by two or more doses over the course of a day. Human administration may be at dosages of from about 10 mg BID to about 1000 mg BID, preferably from about 50 mg BID to about 500 mg BID, more preferably at a dose of from about 100 mg BID to about 300 mg BID. [0100]
  • Compounds as described in U.S. Pat. No. 5,384,330, including retigabine, can be administered orally using conventional pharmaceutical excipients or carriers, preferably coated or contained in hard or soft gelatin capsules. Examples of oral formulations contained in hard gelatin capsules can include those in which the active compound comprises from about 45% to 50%, by weight, of the formulation. Microcrystalline cellulose comprises from about 43% to about 47%, povidone comprises from about 3% to about 4%, and silicon dioxide and magnesium stearate each comprise from about 0.3% to about 0.7%, each by weight. Specific examples of capsules containing 50 mg, 100 mg and 200 mg may be formulated utilizing the following lists of components. [0101]
    Ingredient Amount/Capsule
    50 mg Retigabine Capsules
    Retigabine 50.0 mg
    Microcrystalline Cellulose, NF 45.5 mg
    Povidone, USP 3.5 mg
    Silicon Dioxide, Colloidal, anhydrous, NF 0.5 mg
    Magnesium Stearate, EP 0.5 mg
    Theoretical Fill Weight 100 mg
    100 mg Retigabine Capsules
    Retigabine 100.0 mg
    Microcrystalline Cellulose, NF 91.0 mg
    Povidone, USP 7.0 mg
    Silicon Dioxide, Colloidal, anhydrous, NF 1.0 mg
    Magnesium Stearate, EP 1.0 mg
    Theoretical Fill Weight 200 mg
    200 mg Retigabine Capsules
    Retigabine 200.0 mg
    Microcrystalline Cellulose, NF 182.0 mg
    Povidone, USP 14.0 mg
    Silicon Dioxide, Colloidal, anhydrous, NF 2.0 mg
    Magnesium Stearate, EP 2.0 mg
    Theoretical Fill Weight 400 mg
  • The ingredients in the formulations above can be prepared using the following steps. [0102]
  • 1 ) Weigh separately the active ingredient (retigabine), preferably screened through an 800 micron screen, and the microcrystalline cellulose components. [0103]
  • 2) Prepare a granulation solution by dissolving the Povidone, USP in purified water. [0104]
  • 3) Place the ingredients from Step [0105] 1 into a suitable blender and mix thoroughly.
  • 4) Screen the mixture from Step [0106] 3 through a 1000 μm screen and place the screened mixture into the vessel of a fluidized bed granulator.
  • 5) Heat the ingredients in the fluid bed granulator up to 27° C. product temperature while mixing. [0107]
  • 6) Add the granulation solution from Step [0108] 2 to the fluid bed.
  • 7) Dry the granulate in the fluid bed. [0109]
  • 8) Weigh the colloidal silicon dioxide component, preferably screened through a 1000 μm screen, and the magnesium stearate component, preferably screened through a 600 μm screen. 9) Add the silicon dioxide and magnesium stearate components to the fluid bed granulator's vessel containing the dried granulate from Step [0110] 7 and mix the components thoroughly.
  • 10) Screen the mixed components from Step [0111] 9, preferably through a 800 μm screen.
  • 11) Transfer the final screened components into a suitable blender and mix thoroughly. [0112]
  • The final component mixture from Step [0113] 11 can then be coated, encapsulated or compressed into tablets utilizing conventional tablet excipients or carriers, as desired. It will be understood that oral dosage forms within the scope of this invention can be prepared using the components listed above in respective amounts according the dose of active ingredient in the particular formulation. For veterinary uses, the final mixture of Step 11 can be administered neat or mixed into foods acceptable to the animal in question. Further, the mixtures can be formulated into tablets, capsules or coated products, as described above, or integrated into conventional veterinary medicaments or food products.
  • For intravenous administration, the compounds from U.S. Pat. No. 5,384,330 described herein may be prepared and maintained in conventional lyophylized formulations and reconstituted prior to administration with an intravenously acceptable saline solution, such as a 0.9% saline solution. The pH of the intravenous formulation can be adjusted, as needed, with an intravenous and pharmaceutically acceptable acid, such as methanesulfonic acid. [0114]
  • The following demonstrates the ability of retigabine to open KCNQ potassium channels in mammalian tissue. [0115]
  • KNCQ1, 3 and 5 expression and M-current activity in rat urinary bladder [0116]
  • Using quantitative rtPCR, the expression of KCNQ1, KCNQ3 and KCNQ5 potassium channels was identified in the rat urinary bladder. The highest levels of expression were seen in KCNQ5 (0.2±0.1 ng KCNQ5 mRNA/GAPDH mRNA). To further probe M-current activity in the bladder, retigabine (10 μM, M-current agonist) was tested in isolated bladder smooth muscle cells using standard patch-clamp techniques. Exposure to retigabine significantly increased an outward current that was insensitive to iberiotoxin and was associated with a membrane hyperpolarization of 17.8±3.0 mV (n=5). This hyperpolarization was reversed by the addition of linopirdine (50 μM an M-current antagonist) to the tissue bath. Retigabine relaxed isolated carbachol contracted rat bladder strips with an IC[0117] 50 of 3.5±0.9 μM (n=14). This relaxation was reversed by the M-current blockers linopirdine and XE-991.
  • KCNQ potassium channel activity in guinea pig ileum [0118]
  • Following the procedures of the previous example, the effects of retigabine on isolated precontracted guinea pig ileum preparations were studied. Sections of ileum were isolated from male guinea pigs and suspended in a tissue bath. One end of the tissue was anchored to the bottom of the bath, and the other end to a force transducer. Tissues were contracted with either 20 mM KCl or 200 nM carbachol. The KCNQ channel agonist retigabine was added to the tissue baths in increasing concentrations. Retigabine produced a concentration-dependent inhibition of contraction as follows: [0119]
    KCI Contracted IC50 = 7.1 ± 2
    Carbarchol Contracted IC50 = 5.4 ± 2
  • Both responses to retigabine were antagonized by the KNCQ channel blocker XE-991. [0120]

Claims (23)

What is claimed:
1. A method of treatment or inhibition of hyperactive gastric motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of a KCNQ potassium channel agonist.
2. The method of claim 1 wherein the KCNQ potassium channel is a KCNQ4 potassium channel.
3. The method of claim 1 wherein the KCNQ potassium channel is a KCNQ⅔ potassium channel.
4. The method of claim 1 wherein the KCNQ potassium channel is a KCNQ⅗ potassium channel.
5. The method of claim 1 wherein the hyperactive gastric motility in a mammal is associated with inflammatory bowel disease.
6. The method of claim 1 wherein the hyperactive gastric motility in a mammal is associated with Crohn's disease.
7. A method of treatment or inhibition of hyperactive gastric motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of a compound of the formula:
Figure US20020183395A1-20021205-C00012
wherein:
R1 is selected from hydrogen, C1—C6-alkyl, C2—C6-alkanoyl or the radical Ar;
R2 is selected from hydrogen or C1—C6-alkyl;
R3 is selected from C1—C6-alkoxy, NH2, C1—C6-alkylamino, C1—C6-dialkylamino, amino substituted by the radical Ar, C1—C6-alkyl, C2—C6-alkenyl, C2—C6-alkynyl, the radical Ar or the radical ArO—;
R4 is selected from hydrogen, C1—C6-alkyl or the radical Ar;
R5 is selected from hydrogen or C1—C6-alkyl or the radical Ar; Alk: a straight or branched alkylene group with 1-0 carbon atoms, which can also be substituted by the radical Ar;
Ar is a phenyl radical substituted by the radicals R6, R7 and/or R8 where these radicals R6, R7 and R8 are the same or different and represent C1—C6-alkyl, C3—C7-cycloalkyl, hydroxy, C1—C6-alkoxy, C2—C6-alkanoyloxy, halogen, hydroxy, C1—C6-halogenoalkyl, —CN, —NH2, —NH—C1—C6-alkyl, —N(C1—C6-alkyl)2, —CO2H, —CO—C1—C6-alkyl, —CO—O—C1—C6-alkyl, —COAr, —CO—OAr, —CONH2, —CONH—C1—C6-alkyl, —CON(C1—C6-alkyl)2, —CONHAr, —NH—CO—C1—C6-alkyl, —NHCO—Ar, —NHCO—C1—C6-alkoxy, —N—H—CO—Ar, —N HCO—NH2, —NHCO—N(—C1—C6-alkyl)2, —NHCO—NHAr, —NH—SO2—C—1—C6-alkyl, —NH—SO2Ar, —NH—SO2-nitrophenyl, —SO2—OH, —SO2—C1—C6-alkyl, —SO2—Ar, —SO2—C1—C6-alkoxy, —SO2—OAr, —SO2—NH2, —SO2—NH—C1—C6-alkyl, —SO2—N(C1—C6-alkyl)2, —SO2—NHAr, —SO2—C1—C6-alkoxy;
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.
8. A method of claim 7 in which the compound is selected from the group of:
2-Amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene;
2-Amino-4-(4-trifluoromethylbenzylamino)-1-ethoxycarbonylamino-benzene;
2-Amino-4-benzylamino-1-ethoxycarbonylamino-benzene;
2-Amino-4-(3,5-dichlorobenzylamino)-1-ethoxycarbonylamino benzene;
2-Amino-4-(3,5-dichlorobenzylamino)-1-propyloxycarbonylamino benzene;
2-Amino-(2-chlorobenzylamino)-1-(diethylcarbamoylamino) benzene;
2-Amino-4-(2,4-dichlorobenzylamino)-1-(dimethylcarbamoylamino) benzene; or
1,2-Diacetylamino-4-(4-fluorobenzylamino) benzene;
or a pharmaceutically acceptable salt thereof.
9. The method of Claim of claim 8 wherein the mammal is a human.
10. The method of claim 8 wherein the mammal is feline or canine.
11. The method of claim 8 wherein the hyperactive gastric motility in a mammal is associated with inflammatory bowel disease.
12. The method of claim 8 wherein the hyperactive gastric motility in a mammal is associated with Crohn's disease.
13. A method of treatment or inhibition of hyperactive gastric motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid or a pharmaceutically acceptable salt or ester form thereof.
14. The method of claim 13 wherein the pharmaceutically acceptable ester form is N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester.
15. The method of Claim of claim 13 wherein the mammal is a human.
16. The method of claim 13 wherein the hyperactive gastric motility in a mammal is associated with inflammatory bowel disease.
17. The method of claim 13 wherein the hyperactive gastric motility in a mammal is associated with Crohn's disease.
18. A method of treatment or inhibition of hyperactive gastric motility in a mammal, the method comprising administering to a mammal in need thereof a pharmacologically effective amount of a compound of the formula:
Figure US20020183395A1-20021205-C00013
wherein:
R is hydrogen, hydroxy or fluoro;
R1, R2, R3 and R4 each are independently hydrogen, C1-4 alkyl, halogen, trifluoromethyl, phenyl, p-methylphenyl or p-trifluoromethylphenyl; or R1 and R2, R2 and R3 or R3 and R4 are joined together to form a benzo fused ring;
R5 is hydrogen or C1-4 alkyl; and
R6 is chlorine or trifluoromethyl;
or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof..
19. The method of treatment or inhibition of hyperactive gastric motility in a mammal of claim 18 wherein the compound is selected from the group of:
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-3-hydroxy-2-H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-7-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4-trifluoromethyl)2H-indol-2-one;
(±)-1,3-Dihydro-3-hydroxy-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-4,6-bis(trifluoromethyl)-2H-indol-2-one;
(−)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one;
(−)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[g]indol-2one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-phenyl-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[g]indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-phenyl-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-iodo-2H-indol-2one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-(4-methylphenyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-7-(trifluoromethyl)-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[e]indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-5-methyl-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-4,6-bis(trifluoromethyl)-2H-indol-2-one;
(±)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-2H-indol-2one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-6-[4-(trifluoromethyl)phenyl]-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-2-one;
(±)-5-Bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-4,6-dichloro-1,3-dihydro-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-6-iodo-2H-indol-2-one;
(±)-3-(5-Chloro-hydroxyphenyl)-1,3-dihydro-6-iodo-2H-indol-2-one;
(±)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one;
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-2H-benz[f]indol-2one; and
(±)-3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benz[f]indol-2-one;
and the pharmaceutically acceptable salt forms thereof.
20. The method of Claim of claim 18 wherein the mammal is a human.
21. The method of claim 18 wherein the mammal is feline or canine.
22. The method of claim 18 wherein the hyperactive gastric motility in a mammal is associated with inflammatory bowel disease.
23. The method of claim 18 wherein the hyperactive gastric motility in a mammal is associated with Crohn's disease.
US10/114,148 2001-04-04 2002-04-02 Methods for treating hyperactive gastric motility Abandoned US20020183395A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/114,148 US20020183395A1 (en) 2001-04-04 2002-04-02 Methods for treating hyperactive gastric motility
US10/635,081 US7015242B2 (en) 2001-04-04 2003-08-06 Methods for treating hyperactive gastrointestinal motility
US11/384,895 US20060160892A1 (en) 2001-04-04 2006-03-20 Methods for treating hyperactive gastric motility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28147101P 2001-04-04 2001-04-04
US10/114,148 US20020183395A1 (en) 2001-04-04 2002-04-02 Methods for treating hyperactive gastric motility

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/635,081 Division US7015242B2 (en) 2001-04-04 2003-08-06 Methods for treating hyperactive gastrointestinal motility

Publications (1)

Publication Number Publication Date
US20020183395A1 true US20020183395A1 (en) 2002-12-05

Family

ID=23077446

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/114,148 Abandoned US20020183395A1 (en) 2001-04-04 2002-04-02 Methods for treating hyperactive gastric motility
US10/635,081 Expired - Fee Related US7015242B2 (en) 2001-04-04 2003-08-06 Methods for treating hyperactive gastrointestinal motility
US11/384,895 Abandoned US20060160892A1 (en) 2001-04-04 2006-03-20 Methods for treating hyperactive gastric motility

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/635,081 Expired - Fee Related US7015242B2 (en) 2001-04-04 2003-08-06 Methods for treating hyperactive gastrointestinal motility
US11/384,895 Abandoned US20060160892A1 (en) 2001-04-04 2006-03-20 Methods for treating hyperactive gastric motility

Country Status (4)

Country Link
US (3) US20020183395A1 (en)
AR (1) AR033095A1 (en)
AU (1) AU2002338333A1 (en)
WO (1) WO2002080898A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090547A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060122385A1 (en) * 2004-11-05 2006-06-08 Wyeth Process for preparing quinoline compounds and products obtained therefrom
US20060241176A1 (en) * 2005-04-22 2006-10-26 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060247276A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function
US20060258739A1 (en) * 2005-04-22 2006-11-16 Wyeth Dihydrobenzofuran derivatives and uses therof
US20070027142A1 (en) * 2005-07-26 2007-02-01 Wyeth Diazepinoquinolines, synthesis thereof, and intermediates thereto
US20070167438A1 (en) * 2006-01-13 2007-07-19 Wyeth Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
US20070225278A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
US20070225277A1 (en) * 2006-03-24 2007-09-27 Wyeth Treatment of pain
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US20080139610A1 (en) * 2006-08-23 2008-06-12 Valeant Pharmaceuticals North America Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20080146661A1 (en) * 2006-06-05 2008-06-19 Valeant Pharmaceuticals North America Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
US20080188561A1 (en) * 2006-10-10 2008-08-07 Jean-Michel Vernier N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US20080234334A1 (en) * 2006-11-28 2008-09-25 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20090093630A1 (en) * 2007-09-21 2009-04-09 Wyeth Chiral synthesis of diazepinoquinolines
US20090137635A1 (en) * 2007-08-13 2009-05-28 Valeant Pharmaceuticals International, Inc. Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20110003850A1 (en) * 2006-08-23 2011-01-06 Valeant Pharmaceuticals International, Inc. Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11034665B2 (en) 2017-02-28 2021-06-15 Acousia Therapeutics Gmbh Compounds useful as potassium channel openers
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
US12171759B1 (en) 2021-02-09 2024-12-24 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
US12178811B2 (en) 2019-11-08 2024-12-31 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
US12319657B1 (en) 2019-10-10 2025-06-03 Xenon Pharmaceuticals Inc. Solid state crystalline forms of a selective potassium channel modulator

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600158A (en) * 2005-04-22 2006-11-28 CRYSTALS FORMED OF {[(2R) -7- (2,6-DICLOROPHENYL) -5-FLUORO-2,3-DIHIDRO-1-BENZOFURAN-2-IL] METHYL} AMINA
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
KR20110052641A (en) * 2008-07-18 2011-05-18 베일언트 파마슈티컬스 인터내셔널 Modified Release Formulations and Methods of Use thereof
DE102009013613A1 (en) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Dry processing of retigabine
DE102009013611A1 (en) 2009-03-17 2010-09-23 Ratiopharm Gmbh Solid retigabine in non-crystalline form
DE102009013612A1 (en) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabine tablets, preferably with modified release
WO2011039369A2 (en) * 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
EP2536394A2 (en) * 2010-02-19 2012-12-26 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
ES2744315T3 (en) * 2010-10-08 2020-02-24 Ecolab Usa Inc Method for washing and disinfection at low temperature laundry
US20140243350A1 (en) 2011-07-05 2014-08-28 Contera Pharma Aps Use of serotonin receptor agonists for treatment of movement disorders
EP2844639A4 (en) * 2012-04-30 2015-12-23 Scifluor Life Sciences Llc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9220570D0 (en) 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (en) * 1992-01-08 1993-07-15 Asta Medica Ag NEW 1,2,4-TRIAMINOBENZOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (en) * 1995-10-26 1997-04-30 Asta Medica Ag Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases
DE19701694A1 (en) * 1997-01-20 1998-07-23 Asta Medica Ag New modifications of the 2-amino-4- (4-fluorobenzylamino) -l-ethoxycarbonyl-aminobenzen and processes for their preparation
EP1010425B1 (en) * 1997-08-19 2004-03-31 Mitsubishi Chemical Corporation Remedies for irritable bowel syndrome
WO2000033834A1 (en) * 1998-12-04 2000-06-15 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
DK1303269T3 (en) * 2000-06-29 2006-03-20 Neurosearch As 3-substituted oxindole derivatives and their use as KCNQ potassium channel modulators
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323987A1 (en) * 2003-10-03 2010-12-23 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20050090547A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060122385A1 (en) * 2004-11-05 2006-06-08 Wyeth Process for preparing quinoline compounds and products obtained therefrom
US7781427B2 (en) 2004-11-05 2010-08-24 Wyeth Llc Process for preparing quinoline compounds and products obtained therefrom
US7402687B2 (en) 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060258739A1 (en) * 2005-04-22 2006-11-16 Wyeth Dihydrobenzofuran derivatives and uses therof
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
US20060241176A1 (en) * 2005-04-22 2006-10-26 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060247276A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
US20080200541A1 (en) * 2005-04-22 2008-08-21 Wyeth Benzofuranyl Alkanamine Derivatives and Uses Thereof
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function
US20070027142A1 (en) * 2005-07-26 2007-02-01 Wyeth Diazepinoquinolines, synthesis thereof, and intermediates thereto
US7671196B2 (en) 2005-07-26 2010-03-02 Wyeth Llc Diazepinoquinolines, synthesis thereof, and intermediates thereto
US20070167438A1 (en) * 2006-01-13 2007-07-19 Wyeth Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
US20070225278A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
US20070225277A1 (en) * 2006-03-24 2007-09-27 Wyeth Treatment of pain
US20080146661A1 (en) * 2006-06-05 2008-06-19 Valeant Pharmaceuticals North America Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20110207812A1 (en) * 2006-06-05 2011-08-25 Huanming Chen Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1h-indenes as potassium channel modulators
US8338487B2 (en) 2006-06-05 2012-12-25 Valeant Pharmaceuticals International, Inc. Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8293911B2 (en) 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20080139610A1 (en) * 2006-08-23 2008-06-12 Valeant Pharmaceuticals North America Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US20110003850A1 (en) * 2006-08-23 2011-01-06 Valeant Pharmaceuticals International, Inc. Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US20080188561A1 (en) * 2006-10-10 2008-08-07 Jean-Michel Vernier N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US20080234334A1 (en) * 2006-11-28 2008-09-25 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080318979A1 (en) * 2007-06-13 2008-12-25 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8211918B2 (en) 2007-08-13 2012-07-03 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20110118318A1 (en) * 2007-08-13 2011-05-19 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20090137635A1 (en) * 2007-08-13 2009-05-28 Valeant Pharmaceuticals International, Inc. Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20090093630A1 (en) * 2007-09-21 2009-04-09 Wyeth Chiral synthesis of diazepinoquinolines
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11034665B2 (en) 2017-02-28 2021-06-15 Acousia Therapeutics Gmbh Compounds useful as potassium channel openers
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
US12319657B1 (en) 2019-10-10 2025-06-03 Xenon Pharmaceuticals Inc. Solid state crystalline forms of a selective potassium channel modulator
US12178811B2 (en) 2019-11-08 2024-12-31 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
US12171759B1 (en) 2021-02-09 2024-12-24 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Also Published As

Publication number Publication date
US7015242B2 (en) 2006-03-21
US20040029949A1 (en) 2004-02-12
WO2002080898A3 (en) 2003-08-21
AR033095A1 (en) 2003-12-03
WO2002080898A2 (en) 2002-10-17
US20060160892A1 (en) 2006-07-20
AU2002338333A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
US7015242B2 (en) Methods for treating hyperactive gastrointestinal motility
EP1326597B1 (en) Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function
US6589986B2 (en) Methods of treating anxiety disorders
RU2473343C2 (en) Treating tuberous sclerosis
US7842709B2 (en) Method for treating inflammatory diseases of the digestive tract
US20070270459A1 (en) Overactive bladder treating drug
JP2005527599A (en) Use of zonisamide in obesity and eating disorders
CN102834099A (en) Uses of DGAT1 inhibitors
US20120009183A1 (en) Method for treatment of pancreatitis
EP2059234A1 (en) Method for reducing or alleviating inflammation in the digestive tract
US20040072851A1 (en) Medicinal compositions for treating lower uropathy
WO2000000187A1 (en) Medicinal compositions for treating evacuatory insufficiency
RU2308268C2 (en) Derivatives of aryl- or heteroarylazolyl carbinols for treating incontinence of urine
AU2007204410A1 (en) Combination of mTOR inhibitor and antipolate compound
US20060287395A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
JP4609877B2 (en) Chronic rejection inhibitor
WO2009071096A2 (en) Combination of medical and physical cooling treatment of ischemic effects
JP3154710B1 (en) Lower urinary tract disorders
JPWO2004026296A1 (en) Anti-stress disease composition
CA2559646A1 (en) Medicine for prevention or treatment of frequent urination or urinary incontinence
EP3283066B1 (en) 4-phenylbutyric acid derivatives
WO2005055997A1 (en) Medicinal composition for treating and preventing inflammatory disease
JPWO2006046746A1 (en) Visceral pain prevention / treatment agent
ZA200303798B (en) Methods for modulating bladder function.
ULC Pr MYLAN-TAMSULOSIN

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARGENTIERI, THOMAS M.;REEL/FRAME:012772/0579

Effective date: 20020314

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载